TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group Limited announced the completion of patient enrollment for the clinical study of its innovative temperature-sensitive embolic agent, GPN00289, in China. This product, designed for treating primary liver cancer, combines the benefits of liquid and solid embolization, potentially improving existing treatment methods. The company aims to integrate GPN00289 with its YiGanTai Y-90 microsphere injections to enhance therapeutic effects and expand indications, reinforcing its strategic position in the global liver cancer treatment market.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the nuclear medicine anti-tumor diagnosis and treatment sector. The company focuses on research, development, production, distribution, and sales of innovative medical products, with a global presence supported by R&D centers in Boston and Chengdu, production facilities in Boston, Frankfurt, Singapore, and Chengdu, and a sales network spanning over 50 countries.
Average Trading Volume: 18,825,634
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.99B
See more data about 0512 stock on TipRanks’ Stock Analysis page.